 Alan Palestine
Concepts (683)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 68 | 2023 | 128 | 7.740 |
Why?
| | Panuveitis | 4 | 2023 | 6 | 3.240 |
Why?
| | Fluocinolone Acetonide | 3 | 2023 | 19 | 2.500 |
Why?
| | Uveitis, Intermediate | 4 | 2023 | 8 | 2.380 |
Why?
| | Visual Acuity | 27 | 2024 | 315 | 2.360 |
Why?
| | Cataract | 6 | 2023 | 197 | 2.260 |
Why?
| | Glucocorticoids | 7 | 2023 | 573 | 1.980 |
Why?
| | Fluorescein Angiography | 15 | 2024 | 138 | 1.950 |
Why?
| | Eye Infections, Bacterial | 5 | 2020 | 27 | 1.860 |
Why?
| | Retinopathy of Prematurity | 8 | 2020 | 128 | 1.810 |
Why?
| | Endophthalmitis | 6 | 2020 | 28 | 1.800 |
Why?
| | Macular Edema | 5 | 2023 | 40 | 1.750 |
Why?
| | Scleritis | 3 | 2022 | 19 | 1.660 |
Why?
| | Vitrectomy | 8 | 2020 | 64 | 1.590 |
Why?
| | Corneal Ulcer | 2 | 2022 | 15 | 1.590 |
Why?
| | Tomography, Optical Coherence | 5 | 2024 | 179 | 1.570 |
Why?
| | Macular Degeneration | 9 | 2023 | 158 | 1.490 |
Why?
| | Geographic Atrophy | 5 | 2023 | 66 | 1.350 |
Why?
| | Cytomegalovirus Retinitis | 5 | 2022 | 18 | 1.300 |
Why?
| | Arthritis, Juvenile | 2 | 2022 | 54 | 1.280 |
Why?
| | Vitreous Body | 15 | 2022 | 104 | 1.280 |
Why?
| | Ocular Hypertension | 4 | 2022 | 62 | 1.120 |
Why?
| | Cyclosporins | 31 | 1991 | 59 | 1.020 |
Why?
| | Postoperative Complications | 7 | 2021 | 2500 | 1.010 |
Why?
| | Corneal Transplantation | 4 | 2020 | 13 | 0.990 |
Why?
| | Glaucoma | 3 | 2023 | 217 | 0.960 |
Why?
| | Cataract Extraction | 4 | 2023 | 93 | 0.950 |
Why?
| | Intraocular Pressure | 9 | 2022 | 295 | 0.940 |
Why?
| | Drug Costs | 2 | 2016 | 111 | 0.920 |
Why?
| | Retinal Vessels | 6 | 2021 | 64 | 0.900 |
Why?
| | Uveitis, Posterior | 5 | 2019 | 12 | 0.840 |
Why?
| | Anterior Chamber | 5 | 2021 | 20 | 0.830 |
Why?
| | Inflammation | 10 | 2023 | 2705 | 0.830 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 170 | 0.820 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 576 | 0.820 |
Why?
| | Humans | 170 | 2024 | 129706 | 0.820 |
Why?
| | Antirheumatic Agents | 2 | 2022 | 282 | 0.820 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.820 |
Why?
| | Retinal Detachment | 3 | 2020 | 56 | 0.820 |
Why?
| | Eye Diseases | 10 | 2020 | 78 | 0.810 |
Why?
| | Retinitis | 15 | 1993 | 19 | 0.800 |
Why?
| | Methotrexate | 3 | 2022 | 248 | 0.780 |
Why?
| | Behcet Syndrome | 7 | 2021 | 18 | 0.780 |
Why?
| | Health Care Costs | 2 | 2016 | 405 | 0.770 |
Why?
| | Retrospective Studies | 29 | 2024 | 14669 | 0.770 |
Why?
| | Wet Macular Degeneration | 3 | 2020 | 43 | 0.770 |
Why?
| | Retinal Drusen | 3 | 2021 | 30 | 0.760 |
Why?
| | Drug Implants | 5 | 2022 | 82 | 0.750 |
Why?
| | Retinal Diseases | 6 | 2020 | 86 | 0.750 |
Why?
| | Acquired Immunodeficiency Syndrome | 22 | 1996 | 227 | 0.750 |
Why?
| | Retinal Vasculitis | 1 | 2021 | 9 | 0.740 |
Why?
| | Azathioprine | 2 | 2022 | 51 | 0.730 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.720 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 43 | 0.670 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 76 | 0.650 |
Why?
| | Homosexuality, Male | 1 | 2020 | 180 | 0.640 |
Why?
| | Registries | 4 | 2023 | 2008 | 0.620 |
Why?
| | Practice Patterns, Physicians' | 3 | 2016 | 1287 | 0.600 |
Why?
| | Cytomegalovirus | 3 | 2022 | 159 | 0.580 |
Why?
| | International Classification of Diseases | 1 | 2018 | 124 | 0.580 |
Why?
| | Surveys and Questionnaires | 8 | 2022 | 5396 | 0.570 |
Why?
| | Conjunctivitis | 2 | 2015 | 29 | 0.570 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 210 | 0.570 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 35 | 0.550 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 526 | 0.550 |
Why?
| | Labor, Induced | 1 | 2017 | 31 | 0.550 |
Why?
| | Sarcoidosis | 9 | 2023 | 151 | 0.550 |
Why?
| | Labor, Obstetric | 1 | 2017 | 55 | 0.540 |
Why?
| | Rheumatologists | 1 | 2016 | 15 | 0.540 |
Why?
| | Ophthalmologists | 1 | 2016 | 11 | 0.530 |
Why?
| | Female | 99 | 2024 | 68562 | 0.530 |
Why?
| | Follow-Up Studies | 12 | 2021 | 4939 | 0.530 |
Why?
| | Adult | 72 | 2024 | 35596 | 0.520 |
Why?
| | Aged | 39 | 2024 | 22113 | 0.520 |
Why?
| | Male | 82 | 2024 | 63544 | 0.520 |
Why?
| | Polychondritis, Relapsing | 1 | 2015 | 2 | 0.520 |
Why?
| | Ear Auricle | 1 | 2015 | 11 | 0.510 |
Why?
| | Autoimmune Diseases | 20 | 2009 | 422 | 0.510 |
Why?
| | Vision Disorders | 2 | 2016 | 133 | 0.500 |
Why?
| | Middle Aged | 53 | 2024 | 31103 | 0.500 |
Why?
| | Insurance, Health | 2 | 2016 | 270 | 0.500 |
Why?
| | Neonatal Screening | 4 | 2018 | 163 | 0.480 |
Why?
| | Needles | 1 | 2015 | 57 | 0.480 |
Why?
| | Biopsy, Needle | 1 | 2015 | 192 | 0.480 |
Why?
| | Surgical Wound Infection | 1 | 2018 | 292 | 0.470 |
Why?
| | DNA, Viral | 1 | 2016 | 381 | 0.460 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 997 | 0.460 |
Why?
| | Multimodal Imaging | | | 107 | NaN |
Why?
| | Complement Activation | 3 | 2022 | 359 | 0.430 |
Why?
| | Choroid | 11 | 2021 | 60 | 0.430 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1106 | 0.430 |
Why?
| | Premature Birth | 1 | 2017 | 313 | 0.430 |
Why?
| | Databases, Factual | 1 | 2018 | 1297 | 0.410 |
Why?
| | Aged, 80 and over | 12 | 2021 | 7074 | 0.410 |
Why?
| | Ophthalmology | 3 | 2022 | 79 | 0.410 |
Why?
| | Cytomegalovirus Infections | 12 | 1999 | 194 | 0.400 |
Why?
| | Immunosuppressive Agents | 5 | 2022 | 706 | 0.400 |
Why?
| | Gestational Age | 8 | 2020 | 857 | 0.400 |
Why?
| | Bacteria | 2 | 2018 | 813 | 0.400 |
Why?
| | Melanoma | 1 | 2019 | 735 | 0.400 |
Why?
| | Vaccination | 1 | 2021 | 1362 | 0.400 |
Why?
| | Colorado | 9 | 2022 | 4471 | 0.400 |
Why?
| | Antiviral Agents | 11 | 2022 | 709 | 0.390 |
Why?
| | Skin Neoplasms | 2 | 2019 | 829 | 0.390 |
Why?
| | Steroids | 2 | 2023 | 148 | 0.390 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 2039 | 0.380 |
Why?
| | Placenta | 1 | 2018 | 706 | 0.380 |
Why?
| | Intravitreal Injections | 1 | 2018 | 54 | 0.380 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1719 | 0.370 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2022 | 126 | 0.370 |
Why?
| | Graft Rejection | 3 | 2021 | 569 | 0.360 |
Why?
| | Electronic Health Records | 1 | 2018 | 969 | 0.360 |
Why?
| | Fundus Oculi | 7 | 2021 | 57 | 0.360 |
Why?
| | Macula Lutea | 3 | 2020 | 18 | 0.350 |
Why?
| | Ciliary Body | 9 | 2018 | 33 | 0.350 |
Why?
| | Biomarkers | 5 | 2023 | 3893 | 0.350 |
Why?
| | Trabeculectomy | 2 | 2022 | 73 | 0.340 |
Why?
| | Complement Factor B | 2 | 2022 | 106 | 0.340 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1529 | 0.340 |
Why?
| | Organ Transplantation | 1 | 2021 | 226 | 0.330 |
Why?
| | Ganciclovir | 9 | 2022 | 51 | 0.320 |
Why?
| | Glaucoma, Open-Angle | 2 | 2022 | 103 | 0.310 |
Why?
| | Aqueous Humor | 4 | 2022 | 33 | 0.310 |
Why?
| | Antigens | 14 | 1990 | 346 | 0.310 |
Why?
| | Complement System Proteins | 3 | 2022 | 307 | 0.310 |
Why?
| | United States | 11 | 2023 | 14078 | 0.300 |
Why?
| | Adolescent | 28 | 2024 | 20355 | 0.290 |
Why?
| | Eye Proteins | 7 | 1990 | 84 | 0.290 |
Why?
| | Conjunctival Diseases | 3 | 2017 | 18 | 0.290 |
Why?
| | Incidence | 6 | 2021 | 2658 | 0.290 |
Why?
| | Cyclosporine | 2 | 2022 | 172 | 0.290 |
Why?
| | Retina | 18 | 1993 | 277 | 0.280 |
Why?
| | Birth Weight | 4 | 2020 | 493 | 0.270 |
Why?
| | Uveitis, Anterior | 4 | 2018 | 13 | 0.270 |
Why?
| | Corneal Diseases | 5 | 2017 | 34 | 0.270 |
Why?
| | Child | 21 | 2022 | 20963 | 0.260 |
Why?
| | Risk Factors | 10 | 2020 | 9832 | 0.250 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5050 | 0.250 |
Why?
| | Opportunistic Infections | 4 | 1991 | 46 | 0.250 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 1984 | 7 | 0.250 |
Why?
| | Adalimumab | 2 | 2022 | 45 | 0.250 |
Why?
| | Biological Factors | 2 | 2022 | 37 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 44 | 0.250 |
Why?
| | Bromocriptine | 4 | 1990 | 27 | 0.250 |
Why?
| | Time Factors | 12 | 2021 | 6593 | 0.230 |
Why?
| | Child, Preschool | 9 | 2022 | 10565 | 0.230 |
Why?
| | Young Adult | 7 | 2024 | 12363 | 0.230 |
Why?
| | Retinal Pigment Epithelium | 1 | 2021 | 68 | 0.230 |
Why?
| | Papilledema | 2 | 2024 | 41 | 0.230 |
Why?
| | Tuberculosis, Ocular | | | 8 | NaN |
Why?
| | Specialization | 2 | 2016 | 145 | 0.230 |
Why?
| | Retinal Vein Occlusion | 1 | 2004 | 13 | 0.230 |
Why?
| | Laser Therapy | 5 | 2021 | 126 | 0.220 |
Why?
| | Infant | 9 | 2022 | 9097 | 0.220 |
Why?
| | Interferon-gamma Release Tests | | | 33 | NaN |
Why?
| | Infant, Premature | 2 | 2019 | 541 | 0.220 |
Why?
| | Fluoresceins | 5 | 1989 | 47 | 0.220 |
Why?
| | Optic Disk | 1 | 2024 | 41 | 0.220 |
Why?
| | Cohort Studies | 7 | 2020 | 5410 | 0.220 |
Why?
| | Mycophenolic Acid | 2 | 2022 | 95 | 0.220 |
Why?
| | Infant, Very Low Birth Weight | 3 | 2018 | 68 | 0.210 |
Why?
| | Phacoemulsification | 3 | 2019 | 116 | 0.210 |
Why?
| | Anti-Inflammatory Agents | 3 | 2022 | 471 | 0.210 |
Why?
| | Algorithms | 4 | 2018 | 1632 | 0.210 |
Why?
| | Etanercept | 1 | 2022 | 58 | 0.200 |
Why?
| | Quality of Life | 3 | 2023 | 2712 | 0.200 |
Why?
| | Histocompatibility Antigens Class II | 9 | 1994 | 360 | 0.200 |
Why?
| | Foscarnet | 4 | 1996 | 20 | 0.200 |
Why?
| | Eye Neoplasms | 3 | 2017 | 17 | 0.200 |
Why?
| | Reference Standards | 2 | 2022 | 168 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Albumins | 1 | 2022 | 103 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 10 | 0.190 |
Why?
| | Tacrolimus | 1 | 2022 | 146 | 0.190 |
Why?
| | Eye Infections, Viral | 2 | 1991 | 7 | 0.190 |
Why?
| | Capsule Opacification | 1 | 2021 | 20 | 0.190 |
Why?
| | Treatment Outcome | 9 | 2022 | 10299 | 0.190 |
Why?
| | Antibodies, Monoclonal | 12 | 2020 | 1360 | 0.190 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 23 | 0.180 |
Why?
| | Rats, Inbred Lew | 18 | 1994 | 91 | 0.180 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | T-Lymphocytes, Helper-Inducer | 8 | 1994 | 137 | 0.180 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 1849 | 0.180 |
Why?
| | Laser Coagulation | 2 | 2018 | 57 | 0.180 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2020 | 16 | 0.170 |
Why?
| | Administration, Topical | 4 | 2016 | 148 | 0.170 |
Why?
| | Anemia, Sickle Cell | 1 | 2004 | 280 | 0.170 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.170 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 22 | 0.170 |
Why?
| | Endotoxins | 3 | 1991 | 222 | 0.170 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 37 | 0.170 |
Why?
| | Multiple Sclerosis | 3 | 2023 | 429 | 0.170 |
Why?
| | Canada | 1 | 2020 | 355 | 0.160 |
Why?
| | Infant, Newborn | 7 | 2020 | 5752 | 0.160 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 34 | 0.160 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 214 | 0.160 |
Why?
| | Complement C3a | 1 | 2019 | 41 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1208 | 0.160 |
Why?
| | Acyclovir | 5 | 2001 | 104 | 0.160 |
Why?
| | Prospective Studies | 6 | 2020 | 7131 | 0.160 |
Why?
| | Pyrimidinones | 1 | 2019 | 102 | 0.160 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 51 | 0.150 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 141 | 0.150 |
Why?
| | Computer Systems | 1 | 2018 | 48 | 0.150 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.150 |
Why?
| | Decision Making | 2 | 2016 | 842 | 0.150 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 222 | 0.150 |
Why?
| | Viral Load | 2 | 2016 | 449 | 0.150 |
Why?
| | Organophosphonates | 1 | 1998 | 91 | 0.150 |
Why?
| | Rats | 24 | 1994 | 5244 | 0.150 |
Why?
| | Disease-Free Survival | 1 | 2019 | 658 | 0.150 |
Why?
| | Risk | 4 | 2018 | 871 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 307 | 0.140 |
Why?
| | Biological Products | 1 | 2021 | 202 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 180 | 0.140 |
Why?
| | Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.140 |
Why?
| | Reoperation | 1 | 2020 | 555 | 0.140 |
Why?
| | Amnion | 1 | 2017 | 25 | 0.140 |
Why?
| | Synovitis | 1 | 2017 | 27 | 0.140 |
Why?
| | Arrestin | 13 | 1990 | 13 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1379 | 0.140 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 38 | 0.140 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 32 | 0.140 |
Why?
| | Parity | 1 | 2017 | 121 | 0.140 |
Why?
| | Cicatrix | 1 | 2017 | 58 | 0.130 |
Why?
| | Medical Informatics | 1 | 2017 | 99 | 0.130 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 134 | 0.130 |
Why?
| | Herpes Zoster | 2 | 2009 | 349 | 0.130 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1047 | 0.130 |
Why?
| | Terminology as Topic | 1 | 2017 | 205 | 0.130 |
Why?
| | Arthritis | 1 | 2017 | 113 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2022 | 399 | 0.130 |
Why?
| | Transplantation, Homologous | 2 | 2016 | 404 | 0.130 |
Why?
| | Lymphocytes | 9 | 1991 | 369 | 0.130 |
Why?
| | T-Lymphocytes | 12 | 2022 | 1911 | 0.130 |
Why?
| | Disease Management | 1 | 2019 | 596 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 643 | 0.120 |
Why?
| | Endoscopy | 1 | 2018 | 268 | 0.120 |
Why?
| | Microbiological Techniques | 1 | 2015 | 30 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 170 | 0.120 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 117 | 0.120 |
Why?
| | Weight Gain | 2 | 2016 | 505 | 0.120 |
Why?
| | Pregnancy | 2 | 2018 | 6274 | 0.120 |
Why?
| | Rheumatology | 1 | 2016 | 106 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 308 | 0.120 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 141 | 0.120 |
Why?
| | Phosphonoacetic Acid | 2 | 1991 | 10 | 0.120 |
Why?
| | Lymphocyte Activation | 8 | 1990 | 1095 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 564 | 0.110 |
Why?
| | Chorioretinitis | 2 | 1992 | 3 | 0.110 |
Why?
| | Toxoplasmosis, Ocular | 2 | 1994 | 2 | 0.110 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 384 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3054 | 0.110 |
Why?
| | Fetus | 1 | 2018 | 765 | 0.110 |
Why?
| | Physicians | 1 | 2022 | 852 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 311 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 870 | 0.110 |
Why?
| | Lymphoma, B-Cell | 2 | 1993 | 102 | 0.110 |
Why?
| | Kidney Diseases | 6 | 1989 | 367 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1998 | 1049 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1048 | 0.100 |
Why?
| | HIV-1 | 1 | 1998 | 841 | 0.100 |
Why?
| | Health Surveys | 1 | 2014 | 488 | 0.100 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 113 | 0.100 |
Why?
| | Patient Selection | 1 | 2016 | 685 | 0.100 |
Why?
| | Iris | 3 | 1991 | 20 | 0.100 |
Why?
| | Creatinine | 7 | 1992 | 485 | 0.100 |
Why?
| | HLA Antigens | 7 | 1991 | 236 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 3297 | 0.100 |
Why?
| | Pars Planitis | 1 | 1992 | 1 | 0.100 |
Why?
| | Mothers | 1 | 2018 | 725 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 1991 | 9 | 0.100 |
Why?
| | Injections, Intravenous | 7 | 1999 | 201 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2022 | 230 | 0.090 |
Why?
| | Capillary Permeability | 2 | 1991 | 141 | 0.090 |
Why?
| | Animals | 34 | 2021 | 34733 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 607 | 0.090 |
Why?
| | HIV | 4 | 2020 | 224 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1570 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 1026 | 0.090 |
Why?
| | Bacterial Infections | 3 | 1989 | 240 | 0.090 |
Why?
| | Antigens, Surface | 3 | 1989 | 149 | 0.090 |
Why?
| | Toxoplasma | 2 | 1994 | 39 | 0.090 |
Why?
| | Cytophagaceae | 1 | 1990 | 1 | 0.090 |
Why?
| | Capnocytophaga | 1 | 1990 | 2 | 0.090 |
Why?
| | Granuloma | 4 | 2023 | 89 | 0.080 |
Why?
| | Urine | 1 | 1989 | 57 | 0.080 |
Why?
| | Antigens, Protozoan | 1 | 1989 | 27 | 0.080 |
Why?
| | Sebaceous Gland Neoplasms | 1 | 1989 | 2 | 0.080 |
Why?
| | Eyelid Neoplasms | 1 | 1989 | 8 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 1989 | 94 | 0.080 |
Why?
| | Odds Ratio | 4 | 2019 | 1025 | 0.080 |
Why?
| | Drug Therapy, Combination | 5 | 1998 | 1024 | 0.080 |
Why?
| | Tonometry, Ocular | 2 | 2019 | 87 | 0.080 |
Why?
| | Eye | 7 | 1988 | 104 | 0.070 |
Why?
| | Disease Progression | 1 | 1999 | 2612 | 0.070 |
Why?
| | Postoperative Period | 2 | 2019 | 320 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 4 | 1988 | 1969 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 1991 | 4016 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 828 | 0.070 |
Why?
| | Antibody Formation | 3 | 1985 | 286 | 0.070 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1987 | 18 | 0.070 |
Why?
| | Dextrans | 1 | 1987 | 82 | 0.070 |
Why?
| | Fanconi Syndrome | 1 | 1986 | 2 | 0.070 |
Why?
| | Escherichia coli | 1 | 1991 | 790 | 0.070 |
Why?
| | Autoantibodies | 6 | 1992 | 1463 | 0.070 |
Why?
| | Prednisolone | 2 | 2020 | 80 | 0.070 |
Why?
| | Cell Movement | 2 | 1988 | 934 | 0.070 |
Why?
| | Lymphocyte Transfusion | 1 | 1986 | 20 | 0.070 |
Why?
| | Immunoenzyme Techniques | 8 | 1991 | 210 | 0.060 |
Why?
| | Infliximab | 2 | 2021 | 102 | 0.060 |
Why?
| | Interferometry | 1 | 1985 | 5 | 0.060 |
Why?
| | Lasers | 2 | 1985 | 132 | 0.060 |
Why?
| | Phenotype | 4 | 2022 | 3063 | 0.060 |
Why?
| | Lenses, Intraocular | 2 | 2021 | 43 | 0.060 |
Why?
| | Panophthalmitis | 1 | 1985 | 2 | 0.060 |
Why?
| | Lubricant Eye Drops | | | 9 | NaN |
Why?
| | Uveomeningoencephalitic Syndrome | 3 | 1990 | 7 | 0.060 |
Why?
| | Protein S Deficiency | 1 | 2004 | 7 | 0.060 |
Why?
| | Ophthalmic Solutions | | | 74 | NaN |
Why?
| | Choroiditis | 4 | 1991 | 6 | 0.060 |
Why?
| | Biopsy | 5 | 1993 | 1098 | 0.060 |
Why?
| | Endemic Diseases | | | 32 | NaN |
Why?
| | Myopia | 1 | 1984 | 48 | 0.060 |
Why?
| | Microscopy, Electron | 8 | 1988 | 418 | 0.050 |
Why?
| | Tears | 4 | 1987 | 19 | 0.050 |
Why?
| | Viremia | | | 133 | NaN |
Why?
| | Tretinoin | 1 | 1984 | 125 | 0.050 |
Why?
| | Phagocyte Bactericidal Dysfunction | 1 | 1983 | 12 | 0.050 |
Why?
| | Retinal Artery | 2 | 1987 | 15 | 0.050 |
Why?
| | Ophthalmia, Sympathetic | 3 | 1990 | 3 | 0.050 |
Why?
| | Keratoplasty, Penetrating | 2 | 1994 | 4 | 0.050 |
Why?
| | Immunologic Memory | 1 | 1985 | 335 | 0.050 |
Why?
| | Transplant Recipients | | | 157 | NaN |
Why?
| | Immunocompromised Host | | | 199 | NaN |
Why?
| | Longitudinal Studies | 1 | 1992 | 2670 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 214 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2020 | 3363 | 0.050 |
Why?
| | Immunohistochemistry | 6 | 1993 | 1700 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 1989 | 895 | 0.050 |
Why?
| | Deltaretrovirus | 3 | 1986 | 12 | 0.050 |
Why?
| | Aneurysm | 1 | 1982 | 31 | 0.050 |
Why?
| | Cavernous Sinus | 1 | 1981 | 15 | 0.050 |
Why?
| | 2-Aminopurine | 1 | 2001 | 10 | 0.050 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2001 | 5 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 399 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 160 | 0.050 |
Why?
| | Arteriovenous Fistula | 1 | 1981 | 37 | 0.050 |
Why?
| | Transplantation Tolerance | 1 | 2021 | 34 | 0.050 |
Why?
| | Pigment Epithelium of Eye | 4 | 1990 | 34 | 0.050 |
Why?
| | Abatacept | 1 | 2021 | 47 | 0.050 |
Why?
| | Tertiary Healthcare | 1 | 2020 | 30 | 0.050 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 54 | 0.040 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.040 |
Why?
| | Gonioscopy | 1 | 2020 | 6 | 0.040 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 14 | 0.040 |
Why?
| | Mycobacterium tuberculosis | | | 314 | NaN |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 27 | 0.040 |
Why?
| | Kidney | 3 | 1989 | 1330 | 0.040 |
Why?
| | Amyloidosis | 1 | 2020 | 39 | 0.040 |
Why?
| | Epithelium | 6 | 1991 | 313 | 0.040 |
Why?
| | Carotid Arteries | 1 | 1981 | 207 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 90 | 0.040 |
Why?
| | Immunization, Passive | 3 | 1988 | 83 | 0.040 |
Why?
| | Cornea | 4 | 1989 | 109 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 623 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 327 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 394 | 0.040 |
Why?
| | Sarcoma, Kaposi | 4 | 1999 | 75 | 0.040 |
Why?
| | Hypertension | 5 | 1991 | 1240 | 0.040 |
Why?
| | Cytosine | 1 | 1998 | 46 | 0.040 |
Why?
| | Trabecular Meshwork | 1 | 2019 | 79 | 0.040 |
Why?
| | Predictive Value of Tests | | | 1981 | NaN |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 269 | 0.040 |
Why?
| | Prolactin | 2 | 1988 | 99 | 0.040 |
Why?
| | Conjunctiva | 3 | 1989 | 52 | 0.040 |
Why?
| | Logistic Models | 2 | 2019 | 1980 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 78 | 0.040 |
Why?
| | Retinol-Binding Proteins | 2 | 1988 | 14 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2020 | 474 | 0.040 |
Why?
| | Fluorometholone | 1 | 2017 | 4 | 0.040 |
Why?
| | Group Processes | 1 | 2017 | 55 | 0.040 |
Why?
| | Drug Evaluation | 2 | 1988 | 79 | 0.040 |
Why?
| | Administration, Oral | 3 | 1999 | 790 | 0.030 |
Why?
| | North America | 1 | 2018 | 293 | 0.030 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2017 | 33 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1987 | 137 | 0.030 |
Why?
| | Interferon-gamma | 2 | 1991 | 765 | 0.030 |
Why?
| | HLA-DR Antigens | 5 | 1991 | 226 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 321 | 0.030 |
Why?
| | Properdin | 1 | 1976 | 8 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 723 | 0.030 |
Why?
| | Cytokines | | | 2008 | NaN |
Why?
| | Cattle | 5 | 1991 | 971 | 0.030 |
Why?
| | Rats, Inbred Strains | 5 | 1987 | 365 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 503 | 0.030 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 20 | 0.030 |
Why?
| | Plasma Cells | 2 | 1987 | 65 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 68 | 0.030 |
Why?
| | Proteins | 2 | 2020 | 948 | 0.030 |
Why?
| | Chronic Disease | 4 | 1990 | 1721 | 0.030 |
Why?
| | Magnesium | 2 | 1986 | 152 | 0.030 |
Why?
| | Syndrome | 2 | 1987 | 343 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1507 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 610 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 2744 | 0.030 |
Why?
| | Blood Proteins | 2 | 1989 | 233 | 0.030 |
Why?
| | Glycoproteins | 1 | 1976 | 340 | 0.030 |
Why?
| | Conjunctival Neoplasms | 2 | 1984 | 6 | 0.030 |
Why?
| | Retinal Hemorrhage | 2 | 1986 | 18 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 227 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 1988 | 1442 | 0.030 |
Why?
| | Recurrence | 2 | 1988 | 1016 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 988 | 0.030 |
Why?
| | Granulomatous Disease, Chronic | 2 | 1983 | 53 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 4 | 1989 | 393 | 0.030 |
Why?
| | Models, Biological | 2 | 2016 | 1707 | 0.030 |
Why?
| | Antibodies, Antinuclear | 2 | 1992 | 63 | 0.030 |
Why?
| | Immunity, Cellular | 2 | 1985 | 269 | 0.030 |
Why?
| | Immunization | 2 | 1985 | 423 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 1994 | 380 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1206 | 0.030 |
Why?
| | Dinoprostone | 2 | 1990 | 188 | 0.030 |
Why?
| | Eye Infections | 1 | 1992 | 2 | 0.020 |
Why?
| | Cells, Cultured | 5 | 1991 | 4058 | 0.020 |
Why?
| | Models, Statistical | 1 | 2016 | 632 | 0.020 |
Why?
| | Cell Line | 5 | 1991 | 2768 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 87 | 0.020 |
Why?
| | Epitopes | 3 | 1990 | 468 | 0.020 |
Why?
| | Kinetics | 2 | 1988 | 1620 | 0.020 |
Why?
| | Sepsis | 2 | 1984 | 566 | 0.020 |
Why?
| | Propionibacterium acnes | 1 | 1991 | 9 | 0.020 |
Why?
| | Indomethacin | 2 | 1990 | 78 | 0.020 |
Why?
| | Transforming Growth Factor beta | 2 | 1991 | 462 | 0.020 |
Why?
| | Biological Transport, Active | 1 | 1991 | 72 | 0.020 |
Why?
| | Dogs | 2 | 1990 | 377 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2783 | 0.020 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 1990 | 6 | 0.020 |
Why?
| | Microcirculation | 1 | 1991 | 141 | 0.020 |
Why?
| | B-Lymphocytes | 2 | 1987 | 816 | 0.020 |
Why?
| | Random Allocation | 2 | 1988 | 353 | 0.020 |
Why?
| | Coronary Circulation | 1 | 1991 | 138 | 0.020 |
Why?
| | Cefazolin | 1 | 1990 | 18 | 0.020 |
Why?
| | Endothelium, Corneal | 1 | 1990 | 15 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 1991 | 1306 | 0.020 |
Why?
| | Protein Binding | 2 | 1989 | 2088 | 0.020 |
Why?
| | Fluorescein | 1 | 1989 | 26 | 0.020 |
Why?
| | Keratitis | 2 | 1994 | 12 | 0.020 |
Why?
| | Kidney Function Tests | 2 | 1989 | 149 | 0.020 |
Why?
| | Flow Cytometry | 2 | 1992 | 1151 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 1989 | 166 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 1990 | 163 | 0.020 |
Why?
| | Retroviridae Proteins | 1 | 1989 | 11 | 0.020 |
Why?
| | Hemocyanins | 2 | 1988 | 61 | 0.020 |
Why?
| | Antimetabolites | 1 | 1989 | 22 | 0.020 |
Why?
| | Alkylating Agents | 1 | 1989 | 27 | 0.020 |
Why?
| | Heptanoates | 1 | 1988 | 2 | 0.020 |
Why?
| | Drug Eruptions | 1 | 1989 | 27 | 0.020 |
Why?
| | Interferon Type I | 1 | 1990 | 139 | 0.020 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1989 | 36 | 0.020 |
Why?
| | Suramin | 1 | 1988 | 7 | 0.020 |
Why?
| | Candidiasis | 1 | 1989 | 57 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 1989 | 58 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1989 | 37 | 0.020 |
Why?
| | Receptors, Virus | 1 | 1989 | 81 | 0.020 |
Why?
| | Lens, Crystalline | 1 | 1990 | 94 | 0.020 |
Why?
| | Lung Diseases | 2 | 1986 | 757 | 0.020 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 1989 | 82 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 1988 | 63 | 0.020 |
Why?
| | Corneal Injuries | 1 | 1989 | 34 | 0.020 |
Why?
| | Mycobacterium Infections | 1 | 1989 | 63 | 0.020 |
Why?
| | Placebos | 1 | 1988 | 203 | 0.020 |
Why?
| | Injections | 1 | 1989 | 174 | 0.020 |
Why?
| | Dexamethasone | 2 | 1987 | 331 | 0.020 |
Why?
| | Antigen-Antibody Complex | 2 | 1985 | 84 | 0.020 |
Why?
| | Central Nervous System Diseases | 1 | 1989 | 68 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 1989 | 119 | 0.020 |
Why?
| | Sugar Alcohol Dehydrogenases | 1 | 1987 | 2 | 0.020 |
Why?
| | Imidazolidines | 1 | 1987 | 8 | 0.020 |
Why?
| | Elapid Venoms | 1 | 1987 | 17 | 0.020 |
Why?
| | Blood-Retinal Barrier | 1 | 1987 | 12 | 0.020 |
Why?
| | Colchicine | 1 | 1987 | 26 | 0.020 |
Why?
| | Aldehyde Reductase | 1 | 1987 | 25 | 0.020 |
Why?
| | Specific Gravity | 1 | 1987 | 11 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 1987 | 65 | 0.020 |
Why?
| | Community Health Services | 1 | 2009 | 229 | 0.020 |
Why?
| | Pituitary-Adrenal System | 1 | 1989 | 142 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 1987 | 82 | 0.020 |
Why?
| | Galactosemias | 1 | 1987 | 12 | 0.020 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 1987 | 6 | 0.020 |
Why?
| | Prednisone | 2 | 1986 | 241 | 0.020 |
Why?
| | Herpesviridae Infections | 1 | 1989 | 142 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 371 | 0.020 |
Why?
| | Onchocerciasis | 1 | 1987 | 8 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1989 | 176 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 637 | 0.020 |
Why?
| | Organ Specificity | 1 | 1987 | 296 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1990 | 543 | 0.020 |
Why?
| | Sclera | 1 | 1987 | 36 | 0.020 |
Why?
| | Molecular Weight | 1 | 1987 | 334 | 0.020 |
Why?
| | Heart Rate | 1 | 1991 | 808 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1987 | 156 | 0.020 |
Why?
| | Dihydroergotoxine | 1 | 1986 | 1 | 0.020 |
Why?
| | Imidazoles | 1 | 1987 | 224 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 1990 | 880 | 0.020 |
Why?
| | Indium | 1 | 1986 | 9 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1987 | 214 | 0.020 |
Why?
| | Radioisotopes | 1 | 1986 | 31 | 0.020 |
Why?
| | Muramidase | 1 | 1986 | 74 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 1986 | 30 | 0.020 |
Why?
| | Wound Healing | 1 | 1989 | 310 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3674 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1988 | 348 | 0.020 |
Why?
| | Serum Albumin | 1 | 1986 | 147 | 0.020 |
Why?
| | Reference Values | 4 | 1989 | 792 | 0.020 |
Why?
| | Osteoporosis | 1 | 1989 | 233 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 694 | 0.020 |
Why?
| | Prognosis | 2 | 1985 | 3801 | 0.020 |
Why?
| | Connective Tissue | 1 | 1985 | 39 | 0.020 |
Why?
| | Double-Blind Method | 3 | 2001 | 1871 | 0.020 |
Why?
| | Vascular Diseases | 1 | 1988 | 242 | 0.020 |
Why?
| | Rabbits | 1 | 1986 | 758 | 0.020 |
Why?
| | Acute Disease | 2 | 1987 | 984 | 0.020 |
Why?
| | Tetanus Toxoid | 1 | 1985 | 37 | 0.020 |
Why?
| | Pigmentation Disorders | 1 | 1985 | 9 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1985 | 296 | 0.010 |
Why?
| | Salmonella typhimurium | 1 | 1986 | 175 | 0.010 |
Why?
| | Antibodies | 1 | 1987 | 392 | 0.010 |
Why?
| | Retinitis Pigmentosa | 1 | 1984 | 18 | 0.010 |
Why?
| | Potassium | 1 | 1985 | 140 | 0.010 |
Why?
| | Lymphadenitis | 1 | 1984 | 5 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 1985 | 106 | 0.010 |
Why?
| | Blood Sedimentation | 1 | 1984 | 34 | 0.010 |
Why?
| | Fibrosis | 1 | 1987 | 521 | 0.010 |
Why?
| | Kidney Tubules, Proximal | 1 | 1985 | 124 | 0.010 |
Why?
| | Chlorides | 1 | 1985 | 138 | 0.010 |
Why?
| | Oculomotor Muscles | 1 | 1984 | 39 | 0.010 |
Why?
| | Isotretinoin | 1 | 1984 | 23 | 0.010 |
Why?
| | Peptides | 1 | 1990 | 903 | 0.010 |
Why?
| | Acne Vulgaris | 1 | 1984 | 27 | 0.010 |
Why?
| | Complement C3 | 1 | 1985 | 200 | 0.010 |
Why?
| | Uveal Diseases | 1 | 1983 | 5 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 731 | 0.010 |
Why?
| | Optic Neuritis | 1 | 1984 | 38 | 0.010 |
Why?
| | Chediak-Higashi Syndrome | 1 | 1983 | 7 | 0.010 |
Why?
| | Uric Acid | 1 | 1984 | 158 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 1985 | 261 | 0.010 |
Why?
| | Rats, Inbred BN | 2 | 1994 | 52 | 0.010 |
Why?
| | Anemia | 1 | 1984 | 155 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1989 | 548 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1984 | 137 | 0.010 |
Why?
| | Liver Diseases | 1 | 1986 | 290 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1986 | 1213 | 0.010 |
Why?
| | Fluorometry | 1 | 1981 | 19 | 0.010 |
Why?
| | Immunochemistry | 3 | 1986 | 13 | 0.010 |
Why?
| | Melanosis | 1 | 1981 | 18 | 0.010 |
Why?
| | Liver | 1 | 1990 | 1848 | 0.010 |
Why?
| | Computers | 1 | 1981 | 64 | 0.010 |
Why?
| | Histocytochemistry | 3 | 1986 | 79 | 0.010 |
Why?
| | Eyelid Diseases | 1 | 1981 | 18 | 0.010 |
Why?
| | Edema | 1 | 1982 | 127 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1985 | 842 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2001 | 319 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1182 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1994 | 166 | 0.010 |
Why?
| | HLA-DQ Antigens | 2 | 1991 | 180 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1999 | 104 | 0.010 |
Why?
| | Permeability | 2 | 1987 | 158 | 0.010 |
Why?
| | Arthus Reaction | 2 | 1987 | 8 | 0.010 |
Why?
| | Sucrose | 2 | 1987 | 93 | 0.010 |
Why?
| | Photoreceptor Cells | 2 | 1987 | 15 | 0.010 |
Why?
| | Survival Analysis | 1 | 1999 | 1297 | 0.010 |
Why?
| | Immunologic Techniques | 2 | 1986 | 39 | 0.010 |
Why?
| | Macrophages | 2 | 1994 | 1459 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 1994 | 17 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1994 | 69 | 0.010 |
Why?
| | DNA, Protozoan | 1 | 1994 | 26 | 0.010 |
Why?
| | Tissue Donors | 2 | 1989 | 399 | 0.010 |
Why?
| | Shock, Septic | 1 | 1976 | 205 | 0.010 |
Why?
| | Eye Enucleation | 1 | 1993 | 11 | 0.010 |
Why?
| | Didanosine | 1 | 1993 | 13 | 0.010 |
Why?
| | Viral Proteins | 2 | 1985 | 330 | 0.010 |
Why?
| | Zidovudine | 1 | 1993 | 78 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1993 | 82 | 0.010 |
Why?
| | Mice | 2 | 1986 | 16585 | 0.010 |
Why?
| | Cell Cycle | 1 | 1994 | 581 | 0.010 |
Why?
| | Neutrophils | 2 | 1987 | 1205 | 0.010 |
Why?
| | HLA-DP Antigens | 1 | 1991 | 32 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1991 | 232 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1990 | 11 | 0.010 |
Why?
| | Leukotriene B4 | 1 | 1990 | 41 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 1990 | 123 | 0.010 |
Why?
| | Biological Assay | 1 | 1991 | 117 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1990 | 155 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1990 | 169 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1990 | 89 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1991 | 311 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1990 | 149 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1990 | 148 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1992 | 413 | 0.010 |
Why?
| | Epoprostenol | 1 | 1990 | 135 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1990 | 159 | 0.010 |
Why?
| | Coroners and Medical Examiners | 1 | 1989 | 7 | 0.000 |
Why?
| | Virus Cultivation | 1 | 1989 | 28 | 0.000 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 250 | 0.000 |
Why?
| | Adrenal Cortex | 1 | 1988 | 27 | 0.000 |
Why?
| | Methods | 1 | 1988 | 63 | 0.000 |
Why?
| | Chemical Fractionation | 1 | 1988 | 28 | 0.000 |
Why?
| | Arterioles | 1 | 1988 | 42 | 0.000 |
Why?
| | Survival Rate | 1 | 1993 | 1894 | 0.000 |
Why?
| | Metaraminol | 1 | 1987 | 1 | 0.000 |
Why?
| | Rats, Inbred WKY | 1 | 1987 | 34 | 0.000 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 1988 | 92 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1987 | 43 | 0.000 |
Why?
| | Peroxidases | 1 | 1987 | 30 | 0.000 |
Why?
| | Mannitol | 1 | 1987 | 35 | 0.000 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1988 | 84 | 0.000 |
Why?
| | Cell Membrane Permeability | 1 | 1987 | 82 | 0.000 |
Why?
| | Edetic Acid | 1 | 1987 | 46 | 0.000 |
Why?
| | Propionibacterium | 1 | 1986 | 2 | 0.000 |
Why?
| | AIDS-Related Complex | 1 | 1986 | 3 | 0.000 |
Why?
| | HIV Antigens | 1 | 1987 | 17 | 0.000 |
Why?
| | Serum Albumin, Bovine | 1 | 1987 | 61 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1988 | 330 | 0.000 |
Why?
| | Mitosis | 1 | 1988 | 177 | 0.000 |
Why?
| | Carcinoma | 1 | 1988 | 214 | 0.000 |
Why?
| | Blood-Brain Barrier | 1 | 1987 | 128 | 0.000 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1986 | 43 | 0.000 |
Why?
| | Argon | 1 | 1986 | 21 | 0.000 |
Why?
| | Cell Division | 1 | 1988 | 802 | 0.000 |
Why?
| | Antigens, Viral | 1 | 1987 | 181 | 0.000 |
Why?
| | Agranulocytosis | 1 | 1986 | 32 | 0.000 |
Why?
| | Homosexuality | 1 | 1986 | 16 | 0.000 |
Why?
| | Interleukin-1 | 1 | 1990 | 972 | 0.000 |
Why?
| | Hydrogen Peroxide | 1 | 1987 | 310 | 0.000 |
Why?
| | Amino Acid Sequence | 1 | 1990 | 2051 | 0.000 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1985 | 34 | 0.000 |
Why?
| | Light | 1 | 1988 | 355 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1987 | 463 | 0.000 |
Why?
| | Drug Synergism | 1 | 1986 | 354 | 0.000 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1986 | 173 | 0.000 |
Why?
| | Biomarkers, Tumor | 1 | 1992 | 1171 | 0.000 |
Why?
| | Autoantigens | 1 | 1988 | 412 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1990 | 2848 | 0.000 |
Why?
| | Anterior Eye Segment | 1 | 1985 | 9 | 0.000 |
Why?
| | HLA-B27 Antigen | 1 | 1985 | 15 | 0.000 |
Why?
| | Pilot Projects | 1 | 1990 | 1567 | 0.000 |
Why?
| | Tissue and Organ Procurement | 1 | 1989 | 302 | 0.000 |
Why?
| | DNA | 1 | 1992 | 1406 | 0.000 |
Why?
| | Hyperemia | 1 | 1985 | 48 | 0.000 |
Why?
| | Lymphokines | 1 | 1984 | 126 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1993 | 1137 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1986 | 539 | 0.000 |
Why?
| | Gram-Negative Bacteria | 1 | 1985 | 70 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1991 | 1060 | 0.000 |
Why?
| | Indians, North American | 1 | 1990 | 615 | 0.000 |
Why?
| | Ischemia | 1 | 1987 | 396 | 0.000 |
Why?
| | Hodgkin Disease | 1 | 1986 | 136 | 0.000 |
Why?
| | Monocytes | 1 | 1987 | 554 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 2557 | 0.000 |
Why?
| | Cryptococcosis | 1 | 1984 | 26 | 0.000 |
Why?
| | Lymphatic Diseases | 1 | 1983 | 20 | 0.000 |
Why?
| | Clone Cells | 1 | 1984 | 257 | 0.000 |
Why?
| | alpha 1-Antitrypsin | 1 | 1985 | 111 | 0.000 |
Why?
| | Colitis | 1 | 1986 | 240 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1986 | 607 | 0.000 |
Why?
| | Meningitis | 1 | 1984 | 81 | 0.000 |
Why?
| | Pain | 1 | 1988 | 770 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1984 | 403 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1988 | 638 | 0.000 |
Why?
| | Biomechanical Phenomena | 1 | 1985 | 783 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1241 | 0.000 |
Why?
| | Vasodilation | 1 | 1985 | 480 | 0.000 |
Why?
| | Endothelium, Vascular | 1 | 1988 | 920 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1986 | 1008 | 0.000 |
Why?
| | Pneumonia, Viral | 1 | 1986 | 361 | 0.000 |
Why?
| | Blood Pressure | 1 | 1987 | 1747 | 0.000 |
Why?
| | Killer Cells, Natural | 1 | 1983 | 422 | 0.000 |
Why?
| | Sexual Behavior | 1 | 1984 | 483 | 0.000 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1984 | 376 | 0.000 |
Why?
| | Lung | 1 | 1985 | 3928 | 0.000 |
Why?
|
|
Palestine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|